Biotech Alert: Searches spiking for these stocks today

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:

• Polyrizon (PLRZ), 5,728.31% surge in interest
• Spruce Biosciences (SPRB), 204.14% surge in interest

Pipeline and key clinical candidates for these companies:

Polyrizon is a development stage biotech company specializing in the development of innovative medical device hydrogels delivered in the form of nasal sprays, which form a thin hydrogel-based shield containment barrier in the nasal cavity that can provide a barrier against viruses and allergens from contacting the nasal epithelial tissue. Polyrizon’s proprietary Capture and Contain T, or C&C, hydrogel technology, comprised of a mixture of naturally occurring building blocks, is delivered in the form of nasal sprays, and potentially functions as a “biological mask” with a thin shield containment barrier in the nasal cavity. Polyrizon are further developing certain aspects of our C&C hydrogel technology such as the bioadhesion and prolonged retention at the nasal deposition site for intranasal delivery of drugs.

Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need.

Recent news on these stocks:

December 3

Leerink upgraded Spruce Biosciences to Outperform from Market Perform with a $160 price target. After receiving Breakthrough Therapy Designation, the shares traded up to almost $200 in October 2025. After conducting a $50M PIPE, the stock has traded down to a more attractive valuation, the firm notes. Leerink is intrigued by the late-stage ERT – tralesinidase alfa – for mucopolysaccharidosis type IIIB, especially with shares trading lower than 1.0-time the firm’s peak revenue opportunity.

Polyrizon announced new preclinical data showing its proprietary naloxone hydrogel adheres to nasal tissue longer than an approved and marketed intranasal naloxone spray product. Using an established ex-vivo rabbit nasal mucosa model, researchers evaluated the persistence of Polyrizon’s hydrogel formulation versus commercial product by applying each formulation to mucosal tissue and washing with Simulated Nasal Electrolyte Solution over a 30-minute period. Quantification of residual fluorescence revealed that Polyrizon’s hydrogel maintained higher values of the fluorescence marker when compared to the commercial product, with differences reaching high statistical significance, indicating notably stronger and more durable mucosal retention. The results showed that Polyrizon’s Trap and Target hydrogel exhibited significantly higher mucoadhesion levels compared to the commercial product, supporting potentially prolonged contact at the nasal deposition site and potentially enhancing bioavailability.

December 2

Polyrizon announced the completion of a major manufacturing upscaling milestone for its proprietary nasal-spray product platform. During the upscaling process, Polyrizon and its manufacturing partner transitioned from small-batch laboratory production to a larger-scale, controlled manufacturing run designed to validate key parameters of PL-14 formulation. The milestone demonstrates that the PL-14 formulation can be reliably produced at increased batch volumes while maintaining high-quality specifications. The manufacturing process is set to support the clinical trial material needed for Polyrizon’s clinical trial, which is expected to commence in 2026, offering high-quality and compliant production in line with USA and European regulatory standards.

Hear more from InvestingChannel by signing up for The Spill.

About “Biotech Alert”

The Fly will report on a selection of biotech stocks seeing a surge in interest from retail and financial professional investors, based on data from InvestingChannel.

This Fly exclusive recap reveals the biotech stocks that are seeing a spike in searches among the 20-plus million retail and financial professional investors through InvestingChannel’s online financial news media ecosystem.

This increased attention from the investors may be in response to, or advance of, outsized moves for stocks in the biotech sector, which tend to be volatile and prone to sharp swings in share price around binary events such as clinical study results and FDA approvals.